Arkstone.AI

Name

Arkstone.AI

Legal name

Arkstone Medical Solutions LLC

Website

https://arkstone.ai

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Arkstone.AI provides an AI-powered clinical decision support platform that converts infectious disease laboratory results into evidence-based antibiotic treatment recommendations, serving clinical laboratories, hospitals, and skilled nursing facilities via LIMS integrations.

Ownership category

akta.pro rank

Headquarters

HQ city

Boca Raton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. OneChoice Report Platform: Arkstone generates revenue by providing AI-powered clinical decision support reports to laboratories, hospitals, and healthcare facilities. The platform is delivered as an integrated service with laboratory partners, where Arkstone analyzes lab data and returns actionable OneChoice Reports to healthcare providers. Revenue appears to be derived from service agreements with laboratory and healthcare facility customers, with the platform operating as a B2B SaaS-like model integrated directly into laboratory workflows.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Arkstone provides an AI-powered clinical decision support platform that integrates with laboratory information management systems to transform raw molecular and microbiology diagnostic results into actionable antimicrobial treatment recommendations (OneChoice Reports). Its expert-in-the-loop machine learning system delivers optimal drug, dosage, duration, and route of administration guidance to clinicians, supported by risk scoring (ArkScore), pathogen identification (PathFinder), dosing optimization (RightDose), and antimicrobial stewardship compliance reporting for healthcare facilities.

Product overview

Arkstone.AI is a biotechnology company providing a unified AI-powered clinical decision support platform centered on the OneChoice® Report for infectious disease treatment guidance and antimicrobial stewardship. The core platform analyzes molecular diagnostics (PCR, NGS) and microbiology culture/stain data to generate precision-guided antibiotic recommendations. Key integrated components include ArkScore™ (risk assessment ratings), PathFinder™ (pathogen identification), MedsMatrix™ (visual drug effectiveness table), OneChoice® Plus (interactive web companion), RightDose™ (pediatric/adult dosing), and Antimicrobial Stewardship Reports (facility-level compliance). The platform is FDA-classified as Clinical Decision Support Software and focuses on reducing antibiotic overprescription through expert-in-the-loop machine learning.

Differentiator

Problem solved

Functional benefit

Brands

• OneChoice: Patent-pending AI-powered treatment recommendation system that selects the most appropriate treatment regimen based on organisms present, resistance genes detected, source of infection, diagnosis code, patient demographics, and allergies.
• OneChoice Plus
• ArkScore
• RightDose
• PathFinder
• MedsMatrix

Products and services

• OneChoice Report Patent-pending AI-powered treatment recommendation engine that analyzes laboratory results to provide optimal antibiotic regimen, dosage, duration, and route of administration based on organisms detected, resistance genes, patient demographics, allergies, and diagnosis codes. Used by laboratories, hospitals, and skilled nursing facilities.
• ArkScore Personalized numerical health assessment providing clinicians with antimicrobial risk ratings including Infection Complexity ArkScore, Antimicrobial Resistance ArkScore, and Adverse Reaction ArkScore to help identify potential adverse drug reactions before treatment. Used by prescribing clinicians.
• PathFinder Proprietary algorithm system using supervised machine learning and AI to identify which detected organisms are most likely pathogenic and the focus of treatment, considering sample source context and relevant resistance genes. Used by clinicians interpreting lab results.
• OneChoice Culture Reports OneChoice treatment recommendations extended to microbiology culture and stain results, complementing the existing molecular diagnostics OneChoice reports. Used by laboratories and clinicians to interpret culture-based infectious disease diagnostics.
• OneChoice Plus Interactive web portal companion to the OneChoice Report accessible via QR code. Provides additional information, drug references, drug interaction checks, GFR and CrCL calculators, renal/hepatic dosing guidance, language translations, and links to primary source literature. Used by prescribers at the point of care.
• RightDose Dosing enhancement feature providing tailored antibiotic dosage recommendations for different age groups from neonates to adults, including adjustments for renal and hepatic function. Centralized from a comprehensive antibiotic drug database. Used by prescribers needing precise pediatric and adult dosing guidance.
• Antimicrobial Stewardship Report Facility-level reporting assisting nursing homes and skilled nursing facilities in meeting CMS and Joint Commission antimicrobial stewardship requirements, aligned with CDC core elements for ASP compliance. Used by long-term care facility leadership and compliance teams.
• COVID-19 Reports Specialized COVID-19 Pandemic Alert reports with real-time infection statistics and CDC/FDA treatment recommendations. Used by clinicians managing COVID-19 patients during the pandemic.

Quantifiable outcome

• 97.8% of physicians report improved treatment decisions with OneChoice
• +4 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability5 records

Feature7 records

Partnerships

Two partnerships are on record, tiered core and major.

• DendicoreTechnology or Integration · 15 May 2023Arkstone Medical Solutions and Dendi announced a strategic partnership combining Arkstone's AI technology and infectious disease expertise with Dendi's innovative Laboratory Information System (LIS). The collaboration enables broader deployment of Arkstone's clinical decision support through Dendi's established laboratory customer base.
• AMS OnsitemajorStrategic or Co-development Partner · 19 August 2020AMS Onsite, the leading infection control and prevention practice for America's long-term care facilities, partnered with Arkstone to leverage its proprietary treatment recommendations. The integration allows AMS Onsite to offer targeted antimicrobial treatment recommendations as part of its comprehensive ICP program, reducing antibiotic resistance and improving health outcomes for residents in long-term care and skilled nursing facilities.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

• Xx.com/arkstonemedical
• Facebookfacebook.com/arkstonemedical
• LinkedInlinkedin.com/company/arkstonemedical

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arkstone.AI